Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
- Registration Number
- NCT04773756
- Lead Sponsor
- Alexandria University
- Brief Summary
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
- mild- moderate COVID-19 confirmed by PCR
Exclusion Criteria
- Patients on renal dialysis
- Severe COVID-19 cases
- Patients on amiodarone therapy (given the reported FDA warning of an interaction between amiodarone and sofosbuvir that might lead to severe bradycardia).
- Children < 12 years
- Pregnant and breast feeding women
- Exacerbation of hepatitis B
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Sofosbuvir / Daclatsvir Sofosbuvir 400 MG/ Daclatasvir 60mg A drug used in the treatment of HCV infection, given in the same dose 400mg and 60 mg respectively once daily for 14 days
- Primary Outcome Measures
Name Time Method evaluate the combined effect of Sofosbuvir and Daclatasvir in treatment of patients with mild-moderate Covid-19. it is estimated to be 2 weeks The study assesses the incidence of resolution of symptoms in COVID patients after taking Sofosbuvir and Daclatasvir for 14 days by doing PCR and the result to be negative
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Amr Aly Abd elmoety
🇪🇬Alexandria, Egypt